Neurocrine Biosciences, Inc. [NBIX] stock prices are up 3.99% to $143.03 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The NBIX shares have gain 2.92% over the last week, with a monthly amount glided 3.84%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neurocrine Biosciences, Inc. [NASDAQ: NBIX] stock has seen the most recent analyst activity on April 24, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $170 from $140. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $136 on the stock. Mizuho reiterated its recommendation of a Neutral and raised its price target to $113 on August 21, 2023. SVB Securities upgraded its rating to Outperform for this stock on July 24, 2023, and upped its price target to $125. In a note dated July 06, 2023, BMO Capital Markets upgraded an Market Perform rating on this stock and boosted its target price from $91 to $96.
The stock price of Neurocrine Biosciences, Inc. [NBIX] has been fluctuating between $89.04 and $148.37 over the past year. Currently, Wall Street analysts expect the stock to reach $129.29 within the next 12 months. Neurocrine Biosciences, Inc. [NASDAQ: NBIX] shares were valued at $143.03 at the most recent close of the market. An investor can expect a potential drop of -9.61% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
The Neurocrine Biosciences, Inc. [NASDAQ:NBIX] reported sales of 1.98B for trailing twelve months, representing a surge of 22.57%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.17 and Total Capital is 0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 137.62 points at the first support level, and at 132.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 146.83, and for the 2nd resistance point, it is at 150.63.
Neurocrine Biosciences, Inc. [NBIX] reported earnings per share of $1.44 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.14/share, meaning a difference of $0.3 and a surprise factor of 26.30%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were $0.82 per share as compared to estimates of $0.97 per share, a difference of -$0.15 representing a surprise of -15.50%.
Ratios To Look Out For
It’s worth pointing out that Neurocrine Biosciences, Inc. [NASDAQ:NBIX]’s Current Ratio is 2.52. On the other hand, the Quick Ratio is 2.40, and the Cash Ratio is 0.56. Considering the valuation of this stock, the price to sales ratio is 7.18, the price to book ratio is 6.32 and price to earnings (TTM) ratio is 39.31.
Transactions by insiders
Recent insider trading involved BENEVICH ERIC, Chief Commercial Officer, that happened on Apr 15 ’24 when 19818.0 shares were sold. Chief Regulatory Officer, Delaet Ingrid completed a deal on Apr 01 ’24 to sell 272.0 shares. Meanwhile, Chief Regulatory Officer Delaet Ingrid sold 5000.0 shares on Mar 21 ’24.
